Akeso says ivonescimab plus chemo beat durvalumab plus chemo on overall survival in first-line biliary tract cancer, with Phase III HARMONi-GI1 also hitting PFS and ORR. Durvalumab combo is the guidel

What happened: Akeso (HKEX: 9926.HK) presented Phase III HARMONi-GI1 results at ESMO 2026, showing ivonescimab plus chemotherapy met its primary overall survival endpoint versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer. Key numbers: Median OS 14.9 vs 12.1 months (HR=0.75; P=0.0031), Why it matters: The trial is described as the first Phase III study in biliary tract cancer to show significant positive OS, PFS, and ORR results versus the PD-L1 plus chemotherapy standard of care. It was selected as a Late-Breaking Abstract for the ESMO Presidential Symposium. Market: +3.2% today ($86.55), -23.6% YTD, 1.0x vol — as of 07:45 UTC

Akeso (HKEX: 9926.HK) presented Phase III HARMONi-GI1 results at ESMO 2026, showing ivonescimab plus chemotherapy met its primary overall survival endpoint versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer.

The trial is described as the first Phase III study in biliary tract cancer to show significant positive OS, PFS, and ORR results versus the PD-L1 plus chemotherapy standard of care. It was selected as a Late-Breaking Abstract for the ESMO Presidential Symposium. Market: +3.2% today ($86.55), -23.6% YTD, 1.0x vol — as of 07:45 UTC